NCT06539481 - Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

July 15, 2026

Study Completion Date

October 31, 2028

Conditions

Non-infectious Uveitis Affecting the Posterior Segment of the Eye

Interventions

DRUG

fluocinolone acetonide 190 micrograms

ILUVIEN®, is a tiny tube that is to be implanted in the eye and releases low levels of the corticosteroid (fluocinolone acetonide) in the eye. ILUVIEN® delivers corticosteroid directly to the intended site of action for up to 36 months.

Trial Locations (6)

Unknown

NOT_YET_RECRUITING

Charité - Universitätsmedizin Berlin Institute of Health Department of Ophthalmology, Berlin

RECRUITING

Augenzentrum am St. Franziskus-Hospital Münster, Münster

RECRUITING

Hospital Universitario Cruces, Bilbao

RECRUITING

Fundación Jiménez Díaz, Madrid

RECRUITING

University of Bristol Bristol Medical School, Bristol

RECRUITING

Sheffield Teaching Hospitals NHS Foundation Trust and Sheffield Children NHS Foundation Trust, Sheffield